Speedel shareholders elect four Novartis officers as new members to the board of directors(PresseBox) (Basel, )
Together with the invitation, the Board of Directors of Speedel had recommended the following persons to be elected for a three years term:
- Dr. Raymund Breu - Chief Financial Officer, Novartis International
- Joseph Jimenez - Chief Executive Officer, Novartis Pharma
- Jonathan Peacock - Chief Financial Officer, Novartis Pharma
- Joerg Walther - Global Head, Legal M&A and Antitrust, Novartis International
The proposal of the Board was approved by the shareholders with a strong majority.
After the closing of the EGM the new Board of Directors of Speedel met for its constituent meeting and elected Joseph Jimenez as Chairman and Dr. Fritz Kunz as Vice Chairman. Additionally the new Board decided upon Dr. Andrin Oswald as the new CEO of Speedel.
Dr. Fritz Kunz, Vice Chairman of the Board, commented: "We welcome the new members of the Board and the new CEO. They will lead Speedel through the period of integration."
The Slides presented at the EGM can be accessed on the company's website at http://www.speedel.com/section/6/subsections/8.
Forward looking statements This press release includes forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are based on our current expectations and projections about future events. All statements, other than statements of historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The word "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations described in these forward-looking statements and you should not place undue reliance on them. There can be no assurance that actual results of our research and development activities and our results of operations will not differ materially from these expectations. Factors that could cause actual results to differ from expectations include, among others: our or our partners' ability to develop safe and efficacious products; our or our partners' ability to achieve positive results in clinical trials; our or our partners' ability to obtain marketing approval and market acceptance for our product candidates; our ability to enter into future collaboration and licensing agreements; the impact of competition and technological change; existing and future regulations affecting our business; changes in governmental oversight of pharmaceutical product development; the future scope of our patent coverage or that of third parties; the effects of any future litigation; general economic and business conditions, both internationally and within our industry, including exchange rate variations; and our future financing plans.